What to expect from high throughput genomics in metastatic breast cancers
作者： Concetta Elisa Onesti , Cécile Vicier , Fabrice André
DOI: 10.1016/J.BREAST.2015.07.006
关键词: Comparative genomic hybridization 、 Genomics 、 Gene expression profiling 、 Breast cancer 、 Precision medicine 、 DNA sequencing 、 Exome sequencing 、 Metastatic breast cancer 、 Computational biology 、 Medicine
摘要: Breast cancer is a heterogeneous disease and its genomic characteristics have been widely studied in the last years. Although several progresses made, metastatic still incurable majority of patients. Recent studies shown that large number candidate targets exist breast cancer. Currently only two drivers validated (ER HER2), but others seem to be associated with objective response, such as PIK3CA mutations, FGFR1 amplifications, AKT1 EGFR amplifications ERBB2 mutations. Beside driver identification, many other applications can developed for genomics identification lethal subclones, DNA repair defects or immune response against tumor. Most precision medicine programs currently use targeted sequencing. Nevertheless, whole exome sequencing, RNA gene expression analysis, phosphoprotein detection, SNP arrays ctDNA sequencing also proposed clinical trials.
core.ac.uk
elsevier.com
sci-hub.se 参考文章(54)
Payal D Shah, Mary Ellen Moynahan, Shanu Modi, Betty Ann Caravella, Farrah M Datko, Stephen Zamora, Elizabeth Comen, Theresa Gilewski, Steven M Sugarman, Gabriella D'Andrea, Diana E Lake, Shari B Goldfarb, Sujata Patil, Anne Covey, Michael F Berger, Mario E Lacouture, Larry Norton, Clifford A Hudis, Jose Baselga, Sarat Chandarlapaty, Maura N Dickler, Abstract PD5-3: Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC) Cancer Research. ,vol. 75, ,(2015) , 10.1158/1538-7445.SABCS14-PD5-3
Gabriel N. Hortobagyi, Martine J. Piccart-Gebhart, Hope S. Rugo, Howard A. Burris, Mario Campone, Shinzaburo Noguchi, Alejandra T. Perez, Ines Deleu, Mikhail Shtivelband, Louise Provencher, Norikazu Masuda, Shaker R. Dakhil, Ian Anderson, David Chen, Amy Damask, Alan Huang, Robert McDonald, Tanya Taran, Tarek Sahmoud, José Baselga, Correlation of molecular alterations with efficacy of everolimus in hormone receptor–positive, HER2-negative advanced breast cancer: Results from BOLERO-2. Journal of Clinical Oncology. ,vol. 31, pp. 142- 142 ,(2013) , 10.1200/JCO.2013.31.15_SUPPL.LBA509
Geoffrey Y. Ku, Jianda Yuan, David B. Page, Sebastian E. A. Schroeder, Katherine S. Panageas, Richard D. Carvajal, Paul B. Chapman, Gary K. Schwartz, James P. Allison, Jedd D. Wolchok, Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival Cancer. ,vol. 116, pp. 1767- 1775 ,(2010) , 10.1002/CNCR.24951
Hannah Farmer, Nuala McCabe, Christopher J. Lord, Andrew N. J. Tutt, Damian A. Johnson, Tobias B. Richardson, Manuela Santarosa, Krystyna J. Dillon, Ian Hickson, Charlotte Knights, Niall M. B. Martin, Stephen P. Jackson, Graeme C. M. Smith, Alan Ashworth, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature. ,vol. 434, pp. 917- 921 ,(2005) , 10.1038/NATURE03445
Philip J Stephens, Patrick S Tarpey, Helen Davies, Peter Van Loo, Chris Greenman, David C Wedge, Serena Nik-Zainal, Sancha Martin, Ignacio Varela, Graham R Bignell, Lucy R Yates, Elli Papaemmanuil, David Beare, Adam Butler, Angela Cheverton, John Gamble, Jonathan Hinton, Mingming Jia, Alagu Jayakumar, David Jones, Calli Latimer, King Wai Lau, Stuart McLaren, David J McBride, Andrew Menzies, Laura Mudie, Keiran Raine, Roland Rad, Michael Spencer Chapman, Jon Teague, Douglas Easton, Anita Langerød, Oslo Breast Cancer Consortium (OSBREAC) Karesen Rolf 34 35 Schlichting Ellen 34 Naume Bjorn 35 36 Sauer Torill 35 37 Ottestad Lars 36, Ming Ta Michael Lee, Chen-Yang Shen, Benita Tan Kiat Tee, Bernice Wong Huimin, Annegien Broeks, Ana Cristina Vargas, Gulisa Turashvili, John Martens, Aquila Fatima, Penelope Miron, Suet-Feung Chin, Gilles Thomas, Sandrine Boyault, Odette Mariani, Sunil R Lakhani, Marc van de Vijver, Laura van ‘t Veer, John Foekens, Christine Desmedt, Christos Sotiriou, Andrew Tutt, Carlos Caldas, Jorge S Reis-Filho, Samuel AJR Aparicio, Anne Vincent Salomon, Anne-Lise Børresen-Dale, Andrea L Richardson, Peter J Campbell, P Andrew Futreal, Michael R Stratton, None, The landscape of cancer genes and mutational processes in breast cancer Nature. ,vol. 486, pp. 400- 404 ,(2012) , 10.1038/NATURE11017
E. Cha, M. Klinger, Y. Hou, C. Cummings, A. Ribas, M. Faham, L. Fong, Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Science Translational Medicine. ,vol. 6, ,(2014) , 10.1126/SCITRANSLMED.3008211
Fabrice André, Javier Cortés, Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Research and Treatment. ,vol. 150, pp. 1- 8 ,(2015) , 10.1007/S10549-015-3301-Y
Christina Gewinner, Zhigang C. Wang, Andrea Richardson, Julie Teruya-Feldstein, Dariush Etemadmoghadam, David Bowtell, Jordi Barretina, William M. Lin, Lucia Rameh, Leonardo Salmena, Pier Paolo Pandolfi, Lewis C. Cantley, Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling Cancer Cell. ,vol. 16, pp. 115- 125 ,(2009) , 10.1016/J.CCR.2009.06.006
Michael C. Haffner, Timothy Mosbruger, David M. Esopi, Helen Fedor, Christopher M. Heaphy, David A. Walker, Nkosi Adejola, Meltem Gürel, Jessica Hicks, Alan K. Meeker, Marc K. Halushka, Jonathan W. Simons, William B. Isaacs, Angelo M. De Marzo, William G. Nelson, Srinivasan Yegnasubramanian, Tracking the clonal origin of lethal prostate cancer Journal of Clinical Investigation. ,vol. 123, pp. 4918- 4922 ,(2013) , 10.1172/JCI70354
Janet E. Dancey, Philippe L. Bedard, Nicole Onetto, Thomas J. Hudson, The Genetic Basis for Cancer Treatment Decisions Cell. ,vol. 148, pp. 409- 420 ,(2012) , 10.1016/J.CELL.2012.01.014